# The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020, Paragraph 175

Extent: E+W+S+N.I.

For regulation 216 (amendment of Schedule 30 (particulars for advertisements to persons qualified to prescribe or supply)) substitute—
“216 In Schedule 30—
(a) in paragraphs 1, 2 and 6, for “marketing authorisation,” substitute “ UK marketing authorisation, EU marketing authorisation ”;
(b) after paragraph 2 insert—
“2A In relation to an advertisement in Great Britain (other than an advertisement falling within the exception in regulation 296) where the medicinal product concerned is authorised under a UKMA(GB), a statement that the product concerned is authorised under a UKMA(GB).”.”.

---
Source: https://www.legislation.gov.uk/uksi/2020/1488/schedule/2/paragraph/175 (the official version)
Page: https://openlegislation.uk/human-medicines-amendment-etc-eu-exit-regulations-2020/schedule-2/paragraph-175
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.